TAKE Quarterly Results
TAKE quarterly results. In Sept 2026, TAKE (TAKE) reported revenue ₹30 Cr and net profit ₹2 Cr — revenue +328.6% YoY. For annual financials, live price and key ratios, visit TAKE screener.
TAKE Quarterly Results — Revenue, Profit & EPS Highlights
TAKE latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore TAKE share price charts to track price trends across different timeframes.
- Revenue of ₹30 Cr in Sept 2026 (-49.2% vs Mar 2026, +328.6% vs Sept 2025)
- Net Profit of ₹2 Cr in Sept 2026 (-50.0% vs Mar 2026, -66.7% vs Sept 2025)
- EBITDA of ₹2 Cr in Sept 2026 (-50.0% vs Mar 2026)
- Operating Margin of 6.0% in Sept 2026 (+8.0pp vs Mar 2026)
- Earnings Per Share of ₹0.15 in Sept 2026 (-48.3% vs Mar 2026)
TAKE Quarterly Results — Revenue, EBITDA, Net Profit & EPS
TAKE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 30 | 59 | 32 | 7 | 2 | -49.2% | 328.6% |
| Net Profit (₹ Cr) | 2 | 4 | 1 | 6 | -5 | - | - |
| EBITDA (₹ Cr) | 2 | 4 | 1 | 7 | -5 | - | - |
| EPS (₹) | 0.15 | 0.29 | 0.07 | 0.43 | -0.33 | - | - |
| Operating Margin (%) | 6.0% | -2.0% | -1.0% | 0.0% | 0.0% | - | - |
TAKE Share Price Trend — 1-Year Movement Across Quarterly Results
TAKE 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. View TAKE 52-week performance for the annual high/low range and current price position.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
TAKE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
TAKE latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1884.9 | 16,617 | 1,995 | +10.6% | - | 12.0% | 227.1 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11180.5 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4689.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 407.4 |
|
Apollo Hospitals
Sept 2026 |
₹132,281.88 Cr | 9200.0 | 7,673 | 660 | +15.2% | - | 8.6% | 209.9 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2294.6 | 2,219 | 436 | +21.7% | - | 19.6% | 280.9 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores